These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 39085480)

  • 21. Developing a RiskScore Model based on Angiogenesis-related lncRNAs for Colon Adenocarcinoma Prognostic Prediction.
    Li X; Lei J; Shi Y; Peng Z; Gong M; Shu X
    Curr Med Chem; 2024; 31(17):2449-2466. PubMed ID: 37961859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy.
    Huang R; Lu X; Sun X; Wu H
    Int J Immunopathol Pharmacol; 2024; 38():3946320241249395. PubMed ID: 38687369
    [No Abstract]   [Full Text] [Related]  

  • 23. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
    Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
    Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.
    Sun Z; Zhao Y; Wei Y; Ding X; Tan C; Wang C
    Front Immunol; 2022; 13():939523. PubMed ID: 36091049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.
    Choi SW; Shin H; Sa JK; Cho HJ; Koo H; Kong DS; Seol HJ; Nam DH
    Cancer Med; 2018 May; 7(5):1774-1783. PubMed ID: 29573206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
    Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
    Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
    Chai Y; Wang C; Liu W; Fan Y; Zhang Y
    J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease.
    Zhao S; Chi H; Yang Q; Chen S; Wu C; Lai G; Xu K; Su K; Luo H; Peng G; Xia Z; Cheng C; Lu P
    Front Immunol; 2023; 14():1090040. PubMed ID: 36825022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.
    Johanns TM; Dunn GP
    Cancer J; 2017; 23(2):125-130. PubMed ID: 28410300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Necroptosis-related Molecular Subtypes and Construction of Necroptosis-related Gene Signature for Glioblastoma Multiforme.
    Li Z; Jin Y; Que T; Zhang XA; Yi G; Zheng H; Yuan X; Wang X; Xu H; Nan J; Chen C; Wu Y; Huang G
    Curr Med Chem; 2024; 31(33):5417-5431. PubMed ID: 37539935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of glioblastoma (GBM) molecular classification methods.
    Lee E; Yong RL; Paddison P; Zhu J
    Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.
    Bi Y; Wu ZH; Cao F
    BMC Cancer; 2022 Mar; 22(1):233. PubMed ID: 35241019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.
    Jajamovich GH; Valiathan CR; Cristescu R; Somayajula S
    J Neurooncol; 2016 Sep; 129(2):289-300. PubMed ID: 27393347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
    Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
    Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
    Front Immunol; 2021; 12():557994. PubMed ID: 34220791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug repurposing for glioblastoma based on molecular subtypes.
    Chen Y; Xu R
    J Biomed Inform; 2016 Dec; 64():131-138. PubMed ID: 27697594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 40. Immune landscape-based machine-learning-assisted subclassification, prognosis, and immunotherapy prediction for glioblastoma.
    Li H; He J; Li M; Li K; Pu X; Guo Y
    Front Immunol; 2022; 13():1027631. PubMed ID: 36532035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.